We are live on ! Find out more
GYRE icon

Gyre Therapeutics

48 hedge funds and large institutions have $23.1M invested in Gyre Therapeutics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4848 (0)

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

0.42% less ownership

Funds ownership: 3.64%3.21% (-0.42%)

8% less capital invested

Capital invested by funds: $25.1M → $23.1M (-$1.97M)

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

Holders
48
Holders Change
Holders Change %
0%
% of All Funds
0.63%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
13
Reduced
16
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$8.58M +$6.45K +850 +0.1%
BlackRock
2
BlackRock
New York
$4.92M -$1.39M -183,212 -22%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$2.8M -$206K -27,089 -7%
State Street
4
State Street
Massachusetts
$1.36M +$37.9K +4,985 +3%
SS
5
SBI Securities
Japan
$1.25M -$489K -64,433 -28%
Charles Schwab
6
Charles Schwab
California
$920K -$45.8K -6,034 -5%
Northern Trust
7
Northern Trust
Illinois
$868K -$205K -26,987 -19%
State of Wisconsin Investment Board
8
State of Wisconsin Investment Board
Wisconsin
$291K +$10.1K +1,330 +4%
Millennium Management
9
Millennium Management
New York
$267K +$271K +35,751 New
Bank of New York Mellon
10
Bank of New York Mellon
New York
$182K +$3.11K +409 +2%
UBS Group
11
UBS Group
Switzerland
$171K +$109K +14,323 +166%
AllianceBernstein
12
AllianceBernstein
Tennessee
$163K +$14.4K +1,900 +10%
SO
13
STRS Ohio
Ohio
$157K +$59.2K +7,800 +59%
Goldman Sachs
14
Goldman Sachs
New York
$135K +$137K +18,034 New
Lazard Asset Management
15
Lazard Asset Management
New York
$111K +$113K +14,932 New
RhumbLine Advisers
16
RhumbLine Advisers
Massachusetts
$100K -$20.9K -2,754 -17%
Barclays
17
Barclays
United Kingdom
$99.9K -$80.5K -10,608 -44%
Jane Street
18
Jane Street
New York
$96.7K +$98.4K +12,958 New
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$92K +$46.6K +6,133 +98%
Deutsche Bank
20
Deutsche Bank
Germany
$81.5K
Fidelity Investments
21
Fidelity Investments
Massachusetts
$76.1K -$5.22K -688 -6%
Morgan Stanley
22
Morgan Stanley
New York
$67K -$200K -26,277 -75%
Bank of America
23
Bank of America
North Carolina
$49.9K +$3.11K +410 +7%
Wells Fargo
24
Wells Fargo
California
$41.5K -$11.1K -1,457 -21%
SOADOR
25
State of Alaska Department of Revenue
Alaska
$38K +$39.6K +5,219 New

GYRE Hedge Fund Activity: Q3 2025 in Review

48 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2025, worth a combined $23.1M — down 7.9% from $25.1M a quarter earlier.

Fund positioning in GYRE was balanced in Q3 2025: 10 funds opened new positions, 10 closed out, 13 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $271K. The largest seller was BlackRock, cutting an estimated $1.39M.

  • 48 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $23.1M of Gyre Therapeutics stock for Q3 2025, down 7.9% quarter-over-quarter.
  • 10 funds opened new Gyre Therapeutics positions in Q3 2025 and 10 closed out, a net change of 0 holders.
  • The largest Gyre Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $271K added.
  • The largest Gyre Therapeutics seller in Q3 2025 was BlackRock, an estimated $1.39M sold.

Based on aggregated 13F filings for Q3 2025.